{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:39:23Z","timestamp":1790624363748,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS126187"],"award-info":[{"award-number":["R01-NS126187"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["R01-DC020724"],"award-info":[{"award-number":["R01-DC020724"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-16-1-0219"],"award-info":[{"award-number":["W81XWH-16-1-0219"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0222"],"award-info":[{"award-number":["W81XWH-20-1-0222"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0222"],"award-info":[{"award-number":["W81XWH-20-1-0222"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>NF2<\/jats:italic>\n                    -related schwannomatosis (\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN) is a debilitating condition, characterized by bilateral vestibular schwannomas (VSs) that progressively cause irreversible sensorineural hearing loss. Current management relies on surgery or radiotherapy, while bevacizumab (\u03b1VEGF) is used off-label, with variable and often transient efficacy. Effective therapies that durably suppress tumor growth and preserve hearing are urgently needed. Although immune checkpoint inhibitors have transformed cancer treatment, their efficacy in non-malignant tumors such as VS remains unclear. Here, we evaluate combined anti-PD1 (\u03b1PD1) and \u03b1VEGF therapy in two syngeneic, immune-competent VS models. Combination treatment significantly outperforms either monotherapy, inhibiting tumor growth and preventing hearing loss. Mechanistically, \u03b1VEGF enhances \u03b1PD1 efficacy by normalizing tumor vasculature, improving drug delivery and immune cell infiltration, and promoting cytotoxicity of T and NK cells via NKG2D upregulation. Combined treatment effectively controls tumor growth that progresses despite anti-VEGF therapy. These findings support \u03b1PD1 and \u03b1VEGF combination therapy as a promising strategy for\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-68865-8","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T10:02:15Z","timestamp":1770804135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss"],"prefix":"10.1038","volume":"17","author":[{"given":"Simeng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai Man Natalie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Oblinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Day C.","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas D.","family":"Landegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Seist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-8184","authenticated-orcid":false,"given":"William","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-2992","authenticated-orcid":false,"given":"Long-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-183X","authenticated-orcid":false,"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"68865_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans, D. G. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J. Rare Dis. 4, 16 (2009).","journal-title":"Orphanet J. Rare Dis."},{"key":"68865_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg-2024-110065","volume":"61","author":"C Forde","year":"2024","unstructured":"Forde, C. et al. NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study. J. Med Genet. 61, 856\u2013860 (2024).","journal-title":"J. Med Genet."},{"key":"68865_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans, D. G. et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol. 26, 93\u201397 (2005).","journal-title":"Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol."},{"key":"68865_CR4","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin, S. R. et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol. 35, e50\u2013e56 (2014).","journal-title":"Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol."},{"key":"68865_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00129492-200403000-00012","volume":"25","author":"A Masuda","year":"2004","unstructured":"Masuda, A., Fisher, L. M., Oppenheimer, M. L., Iqbal, Z. & Slattery, W. H. Hearing changes after diagnosis in neurofibromatosis type 2. Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. [] Eur. Acad. Otol. Neurotol. 25, 150\u2013154 (2004).","journal-title":"Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. [] Eur. Acad. Otol. Neurotol."},{"key":"68865_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrneurol.2011.82","volume":"7","author":"S Ammoun","year":"2011","unstructured":"Ammoun, S. & Hanemann, C. O. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat. Rev. Neurol. 7, 392\u2013399 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"68865_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol. 33, 1046\u20131052 (2012).","journal-title":"Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol."},{"key":"68865_CR8","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin, S. R. et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J. Clin. Oncol. 37, 3446\u20133454 (2019).","journal-title":"J. Clin. Oncol."},{"key":"68865_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358\u2013367 (2009).","journal-title":"N. Engl. J. Med."},{"key":"68865_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"68865_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"68865_CR12","doi-asserted-by":"crossref","unstructured":"Li, B., Jin, J., Guo, D., Tao, Z. & Hu, X. Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials. Cancers 15, 2858 (2023).","DOI":"10.3390\/cancers15102858"},{"key":"68865_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J. Neurooncol. 138, 183\u2013190 (2018).","journal-title":"J. Neurooncol."},{"key":"68865_CR14","doi-asserted-by":"crossref","first-page":"101042831769835","DOI":"10.1177\/1010428317698352","volume":"39","author":"Z Li","year":"2017","unstructured":"Li, Z., Liu, X., Guo, R. & Wang, P. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant schwannomas. Tumour Biol. 39, 1010428317698352 (2017).","journal-title":"Tumour Biol."},{"key":"68865_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13046-022-02473-4","volume":"41","author":"M Amit","year":"2022","unstructured":"Amit, M. et al. Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology. J. Exp. Clin. Cancer Res. 41, 292 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"68865_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/MAO.0b013e3181e40e4f","volume":"31","author":"DJ Archibald","year":"2010","unstructured":"Archibald, D. J. et al. B7-H1 expression in vestibular schwannomas. Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol. 31, 991\u2013997 (2010).","journal-title":"Otol. Neurotol. Off Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol."},{"key":"68865_CR17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202719119","volume":"119","author":"SG Ahmed","year":"2022","unstructured":"Ahmed, S. G. et al. Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. Proc. Natl. Acad. Sci. USA 119, e2202719119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68865_CR18","doi-asserted-by":"crossref","unstructured":"Kouzel Martinez F., Graffeo C. S., Carlstrom L. P., Link M. J. Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. BMJ Case Rep. 14, e241834 (2021).","DOI":"10.1136\/bcr-2021-241834"},{"key":"68865_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"68865_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/85321","volume":"2","author":"V Groh","year":"2001","unstructured":"Groh, V. et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2, 255\u2013260 (2001).","journal-title":"Nat. Immunol."},{"key":"68865_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1074-7613(00)80222-8","volume":"12","author":"A Cerwenka","year":"2000","unstructured":"Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721\u2013727 (2000).","journal-title":"Immunity"},{"key":"68865_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/77793","volume":"1","author":"A Diefenbach","year":"2000","unstructured":"Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N. & Raulet, D. H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1, 119\u2013126 (2000).","journal-title":"Nat. Immunol."},{"key":"68865_CR23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.immuni.2015.11.005","volume":"43","author":"AS Rapaport","year":"2015","unstructured":"Rapaport, A. S. et al. The inhibitory receptor NKG2A sustains virus-specific CD8(+) T cells in response to a lethal poxvirus infection. Immunity 43, 1112\u20131124 (2015).","journal-title":"Immunity"},{"key":"68865_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S0198-8859(00)00198-1","volume":"61","author":"SJ Gobin","year":"2000","unstructured":"Gobin, S. J. & van den Elsen, P. J. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61, 1102\u20131107 (2000).","journal-title":"Hum. Immunol."},{"key":"68865_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/imm.12921","volume":"154","author":"S Kumar","year":"2018","unstructured":"Kumar, S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology 154, 383\u2013393 (2018).","journal-title":"Immunology"},{"key":"68865_CR26","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.4049\/jimmunol.0803900","volume":"182","author":"NT Joncker","year":"2009","unstructured":"Joncker, N. T., Fernandez, N. C., Treiner, E., Vivier, E. & Raulet, D. H. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J. Immunol. 182, 4572\u20134580 (2009).","journal-title":"J. Immunol."},{"key":"68865_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22359-x","volume":"12","author":"S Moradi","year":"2021","unstructured":"Moradi, S. et al. Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C. Nat. Commun. 12, 2173 (2021).","journal-title":"Nat. Commun."},{"key":"68865_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fimmu.2012.00339","volume":"3","author":"J Shaw","year":"2012","unstructured":"Shaw, J. & Kollnberger, S. New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease. Front. Immunol. 3, 339 (2012).","journal-title":"Front. Immunol."},{"key":"68865_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/2326-6066.CIR-18-0442","volume":"7","author":"S Whelan","year":"2019","unstructured":"Whelan, S. et al. PVRIG and PVRL2 are induced in cancer and inhibit CD8(+) T-cell function. Cancer Immunol. Res. 7, 257\u2013268 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"68865_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/2326-6066.CIR-18-0637","volume":"7","author":"D Mittal","year":"2019","unstructured":"Mittal, D. et al. CD96 is an immune checkpoint that regulates CD8(+) T-cell antitumor function. Cancer Immunol. Res. 7, 559\u2013571 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"68865_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1986943","volume":"10","author":"L Gimeno","year":"2021","unstructured":"Gimeno, L. et al. CD8+ T lymphocytes are sensitive to NKG2A\/HLA-E licensing interaction: role in the survival of cancer patients. Oncoimmunology 10, 1986943 (2021).","journal-title":"Oncoimmunology"},{"key":"68865_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2008.03.032","volume":"133","author":"D Martinvalet","year":"2008","unstructured":"Martinvalet, D., Dykxhoorn, D. M., Ferrini, R. & Lieberman, J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 133, 681\u2013692 (2008).","journal-title":"Cell"},{"key":"68865_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440, 890\u2013895 (2006).","journal-title":"Nature"},{"key":"68865_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1084\/jem.20132038","volume":"211","author":"LA Perez-Quintero","year":"2014","unstructured":"Perez-Quintero, L. A. et al. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cgamma, Ca++, and Erk, leading to granule polarization. J. Exp. Med. 211, 727\u2013742 (2014).","journal-title":"J. Exp. Med."},{"key":"68865_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/CCID.S395854","volume":"16","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Li, Y. & Yan, H. Low expression of CLEC2B indicates poor prognosis in melanoma. Clin. Cosmet. Investig. Dermatol. 16, 463\u2013477 (2023).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"68865_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41590-020-00829-6","volume":"22","author":"M Gu","year":"2021","unstructured":"Gu, M. et al. NF-kappaB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat. Immunol. 22, 193\u2013204 (2021).","journal-title":"Nat. Immunol."},{"key":"68865_CR37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254\u2013267 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68865_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109287","volume":"249","author":"GE Gregory","year":"2023","unstructured":"Gregory, G. E., Munro, K. J., Couper, K. N., Pathmanaban, O. N. & Brough, D. The NLRP3 inflammasome as a target for sensorineural hearing loss. Clin. Immunol. 249, 109287 (2023).","journal-title":"Clin. Immunol."},{"key":"68865_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.846804","volume":"14","author":"BJ Seicol","year":"2022","unstructured":"Seicol, B. J., Lin, S. & Xie, R. Age-related hearing loss is accompanied by chronic inflammation in the cochlea and the cochlear nucleus. Front. Aging Neurosci. 14, 846804 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"68865_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19, 75\u201390 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68865_CR41","doi-asserted-by":"crossref","unstructured":"Richardson, D. L., Eskander, R. N. & O\u2019Malley, D. M. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 9, 851\u2013859 (2023).","DOI":"10.1001\/jamaoncol.2023.0197"},{"key":"68865_CR42","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag, G. et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72, 1070\u20131080 (2012).","journal-title":"Cancer Res."},{"key":"68865_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens, J. L. et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat. Commun. 8, 15095 (2017).","journal-title":"Nat. Commun."},{"key":"68865_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"68865_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ceb.2015.06.006","volume":"36","author":"R Hallmann","year":"2015","unstructured":"Hallmann, R. et al. The regulation of immune cell trafficking by the extracellular matrix. Curr. Opin. Cell Biol. 36, 54\u201361 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"68865_CR46","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc. Natl. Acad. Sci. USA 112, 14676\u201314681 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68865_CR47","doi-asserted-by":"crossref","unstructured":"Kabir A. U., Subramanian M., Kwon Y., Choi K. Linking tumour angiogenesis and tumour immunity. Nat. Rev. Immunol. 26, 35\u201351 (2025).","DOI":"10.1038\/s41577-025-01211-z"},{"key":"68865_CR48","doi-asserted-by":"crossref","unstructured":"Webb, M. J. et al. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neuro-Oncol. Adv. 5, vdad123 (2023).","DOI":"10.1093\/noajnl\/vdad123"},{"key":"68865_CR49","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"68865_CR50","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68865_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 24, 228\u2013238 (2023).","journal-title":"Lancet Oncol."},{"key":"68865_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68865_CR53","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo, H. Y., Khan, K. A. & Kerbel, R. S. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat. Rev. Clin. Oncol. 21, 468\u2013482 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68865_CR54","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong, H. K. et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 70, 3483\u20133493 (2010).","journal-title":"Cancer Res."},{"key":"68865_CR55","doi-asserted-by":"crossref","unstructured":"Wu, L. et al. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci. Transl. Med. 13, eabd4816 (2021).","DOI":"10.1126\/scitranslmed.abd4816"},{"key":"68865_CR56","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat. Protoc. 14, 541\u2013555 (2019).","journal-title":"Nat. Protoc."},{"key":"68865_CR57","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc. Natl. Acad. Sci. USA 115, E2077\u2013E2084 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68865_CR58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2217\/imt-2021-0196","volume":"14","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8(+) T cells in lung cancer. Immunotherapy 14, 695\u2013708 (2022).","journal-title":"Immunotherapy"},{"key":"68865_CR59","doi-asserted-by":"publisher","first-page":"e8316","DOI":"10.1371\/journal.pone.0008316","volume":"4","author":"E Chung","year":"2009","unstructured":"Chung, E. et al. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4, e8316 (2009).","journal-title":"PLoS ONE"},{"key":"68865_CR60","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nprot.2009.28","volume":"4","author":"BA Tannous","year":"2009","unstructured":"Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582\u2013591 (2009).","journal-title":"Nat. Protoc."},{"key":"68865_CR61","doi-asserted-by":"publisher","first-page":"E3119","DOI":"10.1073\/pnas.1216078109","volume":"109","author":"DP Kodack","year":"2012","unstructured":"Kodack, D. P. et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. USA 109, E3119\u2013E3127 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68865_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5442","volume":"8","author":"LMN Wu","year":"2022","unstructured":"Wu, L. M. N. et al. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci. Adv. 8, eabo5442 (2022).","journal-title":"Sci. Adv."},{"key":"68865_CR63","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"68865_CR64","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-09-2099","volume":"69","author":"L Xu","year":"2009","unstructured":"Xu, L. et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 69, 7905\u20137910 (2009).","journal-title":"Cancer Res."},{"key":"68865_CR65","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-10-2429","volume":"17","author":"S Liao","year":"2011","unstructured":"Liao, S. et al. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin. Cancer Res. 17, 1415\u20131424 (2011).","journal-title":"Clin. Cancer Res."},{"key":"68865_CR66","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1073\/pnas.1818357116","volume":"116","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA 116, 2210\u20132219 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68865_CR67","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1078-0432.CCR-0953-03","volume":"10","author":"L Xu","year":"2004","unstructured":"Xu, L., Pathak, P. S. & Fukumura, D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3\u2019-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin. Cancer Res. 10, 701\u2013707 (2004).","journal-title":"Clin. Cancer Res."},{"key":"68865_CR68","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/0008-5472.CAN-04-3085","volume":"66","author":"L Xu","year":"2006","unstructured":"Xu, L. et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 66, 3971\u20133977 (2006).","journal-title":"Cancer Res."},{"key":"68865_CR69","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1089\/hum.1998.9.18-2699","volume":"9","author":"L Xu","year":"1998","unstructured":"Xu, L., Xie, K. & Fidler, I. J. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum. Gene Ther. 9, 2699\u20132708 (1998).","journal-title":"Hum. Gene Ther."},{"key":"68865_CR70","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41416-024-02863-9","volume":"131","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer. Br. J. Cancer 131, 1683\u20131693 (2024).","journal-title":"Br. J. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68865-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T10:02:20Z","timestamp":1770804140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68865"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68865-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1148"}}